Trial Profile

EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cobicistat/darunavir (Primary) ; Dolutegravir (Primary) ; Abacavir; Atazanavir; Darunavir; Efavirenz; Elvitegravir; Emtricitabine; Etravirine; Lamivudine; Lopinavir; Nevirapine; Raltegravir; Rilpivirine; Ritonavir; Tenofovir disoproxil fumarate
Indications HIV-1 infections
Focus Therapeutic Use

31 Mar 2022 Status changed from active, no longer recruiting to completed.
04 Feb 2021 Planned End Date changed from 1 Dec 2021 to 1 Jun 2023.
04 Feb 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Jun 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com